<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04267042</url>
  </required_header>
  <id_info>
    <org_study_id>H20-00209</org_study_id>
    <nct_id>NCT04267042</nct_id>
  </id_info>
  <brief_title>Comparing Budesonide Via MAD or INSI Prospective Cohort Study</brief_title>
  <official_title>Prospective Double-Cohort Study: Comparing Efficacy of Budesonide Via MAD or INSI in Post-operative Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Paul's Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Paul's Hospital, Canada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic Rhinosinusitis (CRS) is a common disorder in North America, affecting more than 31&#xD;
      million people annually. Common therapy for CRS includes intranasal corticosteroids (INCS)&#xD;
      such as budesonide. At our centre , the current practice is to administer budesonide two&#xD;
      ways: the mucosal atomization device (MAD), which is a nasal spray or impregnated budesonide&#xD;
      in nasal saline irrigation (INSI), which is a nasal rinse. Our study aims to see which method&#xD;
      of administering budesonide has the best treatment outcomes after sinus surgery. This study&#xD;
      will follow patients over a six-month period of time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) and without nasal polyps (CRSsNP) is&#xD;
      a common condition affecting millions of North Americans. CRS is a multifactorial disease&#xD;
      that causes inflammation within the sinonasal passages. Symptoms include; dysosmia, nasal&#xD;
      blockage, sinus pain, and discolored mucous. Olfactory dysfunction is commonly seen in the&#xD;
      CRS patient population. It is estimated that up to 78% of CRS patients have a decreased sense&#xD;
      of smell. Therefore, validated smell tests such as Sniffin'Sticks have been used to determine&#xD;
      the severity and presence of dysosmia. In addition, patients are frequently colonized with&#xD;
      various bacteria or fungi which may further aggravate patient's symptoms. Together, these&#xD;
      manifestations lead to a decreased quality of life in CRS patients.&#xD;
&#xD;
      The basis of therapy is to increase mucociliary clearance, improve drainage and relieve&#xD;
      obstruction, and eliminate signs of inflammation. Common therapy for the inflamed nasal&#xD;
      mucosal lining includes intranasal corticosteroids (INCS) or systemic corticosteroids.&#xD;
      Budesonide (Pulmicort) is a corticosteroid which is the mainstay treatment for CRS patients.&#xD;
      They have been proven to be very effective in reducing SNOT-22 scores, endoscopic scores, and&#xD;
      reducing recurrence in varying severity and subtype of CRS disease.&#xD;
&#xD;
      The current practice at our institution is to administer budesonide via two modalities: the&#xD;
      mucosal atomization device (MAD, Wolfe-Tory Medical, Salt Lake City, UT) or impregnated&#xD;
      budesonide in nasal saline irrigation (INSI) using a NeilMed squeeze bottle (NeilMed&#xD;
      Pharmaceuticals, Santa Rosa, California). The MAD atomizes the medication into particles from&#xD;
      30-100 um in size thus increasing the surface area for drug absorption. At our centre, INSI&#xD;
      is frequently employed for CRS patients in the acute postoperative period. Postoperative use&#xD;
      of INSI has shown to demonstrate significant improvement in quality of life and endoscopy&#xD;
      findings in CRS patients. However, patients can potentially experience headaches and&#xD;
      discomfort, which can affect their adherence to this treatment regimen. Therefore, for&#xD;
      recalcitrant and non-responsive CRS patients, an alternative treatment method is to utilize&#xD;
      budesonide via a MAD in its concentrated form.&#xD;
&#xD;
      Although there is literature that exemplifies the benefit of adding budesonide to&#xD;
      postoperative management of CRS patients, there is yet to be a study that assesses the most&#xD;
      effective modality of administering the corticosteroid. Therefore, this study aims to&#xD;
      prospectively assess the efficacy of INSI and MAD in delivering high-dose nasal&#xD;
      corticosteroids in CRS patients. By determining which administration technique is more&#xD;
      effective, it will lead to better postoperative outcomes for patients suffering from CRS.&#xD;
      Overall, the investigators hope the results from this study will be a step forward in the&#xD;
      understanding which administration modality of intranasal corticosteroids is most effective&#xD;
      in ameliorating patient disease and quality of life.&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      To compare the postoperative efficacy of budesonide in CRS patients delivered via mucosal&#xD;
      atomization device (MAD) or impregnated budesonide in nasal saline irrigation (INSI).&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      The investigators hypothesize that budesonide delivered via MAD will be more effective&#xD;
      postoperatively at decreasing objective evidence and subjective symptoms of CRS compared to&#xD;
      INSI.&#xD;
&#xD;
      Baseline and Follow-up Visits Evaluation:&#xD;
&#xD;
      The following information will be obtained from each participant&#xD;
&#xD;
      Baseline Demographic data: Age Gender Smoking status&#xD;
&#xD;
      Clinical Data:&#xD;
&#xD;
        -  Modified Lund-Kennedy (MLK) scores&#xD;
&#xD;
        -  Sinonasal cultures&#xD;
&#xD;
        -  Sino-nasal Outcome Test-22 (SNOT-22) and EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) scores&#xD;
&#xD;
        -  Sniffin' Sticks Smell Test&#xD;
&#xD;
        -  Routine Blood work (Only at week 1 and month 6)&#xD;
&#xD;
      Conduct of Study:&#xD;
&#xD;
      This is a prospective randomized double cohort study at the St. Paul's Sinus Centre. Patients&#xD;
      who have an upcoming sinus surgery will be recruited to this study. After the patients have&#xD;
      signed the informed consent form and have undergone sinus surgery, they will have their&#xD;
      baseline visit. Patients will be divided into the MAD or INSI arm randomly. Patients will be&#xD;
      required to take budesonide at least 5 days a week to assure changes seen are directly&#xD;
      correlated to taking budesonide. Baseline will be the 1-week postoperative visit following&#xD;
      the patient's sinus surgery. Further data will be collected at month 3 and lastly at the&#xD;
      patients 6 month follow up visit.&#xD;
&#xD;
      Management of Patient Care&#xD;
&#xD;
      Patients have the right to withdraw from the study at any time. Patients who experience signs&#xD;
      and symptoms of hypersensitivity to iodine, burning, itching, pain redness, tiredness, nausea&#xD;
      or vomiting will be asked to stop the rinses immediately. The reaction will be noted and the&#xD;
      code will be broken so that a discussion can occur between the physician and the patient&#xD;
      regarding the use of iodine with the nasal rinses. Patients who meet any of the exclusion&#xD;
      criteria that were not noted at the beginning of the study will be removed from this study&#xD;
      and the physician will discuss the future management options with the patient.&#xD;
&#xD;
      Sample size:&#xD;
&#xD;
      The investigators expect 60 patients (30 patients per study arm) for the number of&#xD;
      participants in this prospective double cohort.&#xD;
&#xD;
      Analysis:&#xD;
&#xD;
      Descriptive statistics will be used to analyze the baseline characteristic data and the data&#xD;
      from the administered surveys and objective findings of eosinophil and IgE blood work,&#xD;
      cultures, Sniffin' Sticks smell test and MLK scores. In addition, rigorous statistical&#xD;
      analysis will be conducted on the Likert scale-based SNOT-22 and EQ-5D-5L surveys. These&#xD;
      analyses will include cross-tabulations (Pearson's chi square test) and confidence interval&#xD;
      calculations.&#xD;
&#xD;
      Safety Monitoring&#xD;
&#xD;
      Patients who experience signs and symptoms of budesonide reaction will be noted and the code&#xD;
      will be broken so that a discussion can occur between the research supervisor and the patient&#xD;
      regarding the use of the topical iodine.&#xD;
&#xD;
      Patients can contact the office anytime if they notice any of the signs or symptoms of iodine&#xD;
      reaction and will be seen by the research supervisor (or designate) within 24 hours.&#xD;
&#xD;
      Adverse Events (AE's)&#xD;
&#xD;
      All expected and unexpected adverse events will be recorded and graded by the research&#xD;
      supervisor. Stable chronic conditions, which are present prior to the clinical trial entry&#xD;
      and do not worsen, are not considered adverse events and will be accounted for in the&#xD;
      patient's medical history.&#xD;
&#xD;
      Recording/Documentation of Adverse Events&#xD;
&#xD;
      During each patient visit, the research supervisor will ask appropriate questions and perform&#xD;
      a physical exam to elicit any adverse events. The research supervisor will also review blood&#xD;
      work obtained from the patient. All reportable adverse events will be recorded on appropriate&#xD;
      case report form. The research supervisor will also write the stop date, the severity of the&#xD;
      AE and his judgment of the AE's relationship to the study.&#xD;
&#xD;
      Serious Adverse Events (SAE's)&#xD;
&#xD;
      An SAE is defined as an AE meeting one of the following:&#xD;
&#xD;
      Death occurring between Day 0 and 182 days (6 months) of the study. Life Threatening Event&#xD;
      (defined as a participant at immediate risk of death at the time of the event) In-patient&#xD;
      hospitalization or prolongation of existing hospitalization between Day 0 and 42 of the&#xD;
      study.&#xD;
&#xD;
      Results in a persistent or significant disability/incapacity In the event of SAE, the&#xD;
      research supervisor will discuss with the patient (or next of kin) whether there is a&#xD;
      relationship between the study and the SAE. If there is a relationship, the PI will be&#xD;
      responsible for coordinating care for the patient until the SAE has been addressed.&#xD;
&#xD;
      Pregnancy During the Trial Patients will be responsible for determining if they are pregnant&#xD;
      or become pregnant during the study. If patients notify the PI they are pregnant, they will&#xD;
      be removed from the study and the medical management options will be discussed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 3, 2020</start_date>
  <completion_date type="Anticipated">February 3, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 3, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SNOT-22 questionnaire</measure>
    <time_frame>6 months postoperatively</time_frame>
    <description>This is a standard of care form that includes 22 questions about symptoms and social/emotional consequences of your nasal disorder. You will be asked to rate your problems as they have been over the past two weeks. Patients will give a score out of 110 with a higher score relating to worse symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MLK endoscopic scores</measure>
    <time_frame>6 months postoperatively</time_frame>
    <description>This score is based on the endoscopic assessment of polyps, edema, and discharge and are each given score 0-2. A score of 2 indicates a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EQ 5D-5L questionnaireand</measure>
    <time_frame>6 months postoperatively</time_frame>
    <description>This is a questionnaire that asks six multiple-choice questions about your mobility, self-care, usual activities, pain/discomfort, anxiety/depression, and overall health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sniffin' Sticks Smell tests</measure>
    <time_frame>6 months postoperatively</time_frame>
    <description>Many CRS patients have a disturbed/ reduced sense of smell. Sniffn' Sticks is a type of test to assess your sense of smell by using various scented pens. The threshold hold and identification test will be performed. This will give a score out of 32 and a lower score indicates a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sinus cultures</measure>
    <time_frame>6 months postoperatively</time_frame>
    <description>A swab will be taken from your nose to see if there are any bacteria or fungi present.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgE count</measure>
    <time_frame>6 months postoperatively</time_frame>
    <description>Blood will be collected to measure IgE levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eosinophil count</measure>
    <time_frame>6 months postoperatively</time_frame>
    <description>Blood will be collected to measure eosinophil levels.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Rhinosinusitis With Nasal Polyps</condition>
  <condition>Allergic Fungal Sinusitis</condition>
  <arm_group>
    <arm_group_label>Budesonide via Mucosal Atomization Device (MAD)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will administer budesonide using a mucosal atomization device (MAD, Wolfe-Tory Medical, Salt Lake City, UT) once a day at least 5 times a week for 6 months postoperatively. The MAD atomizes the medication into particles from 30-100 um in size thus increasing the surface area for drug absorption.&#xD;
Budesonide is provided in nebules (1mg/2cc). Patients will place two nebules of budesonide into the MAD syringe.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide via nasal saline irrigation (INSI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will administer impregnated budesonide in nasal saline irrigation (INSI) using a NeilMed squeeze bottle (NeilMed Pharmaceuticals, Santa Rosa, California) once a day at least 5 times a week for 6 months postoperatively.&#xD;
Budesonide is provided in nebules (1mg/2cc).Patients will place two nebules of budesonide into the 240mls of saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>Budesonide is a corticosteroid that is commonly used intranasally to treat CRS.</description>
    <arm_group_label>Budesonide via Mucosal Atomization Device (MAD)</arm_group_label>
    <arm_group_label>Budesonide via nasal saline irrigation (INSI)</arm_group_label>
    <other_name>Pulmicort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mucosal Atomization Device</intervention_name>
    <description>MAD is a device used as an addition to a syringe to atomize medication to increase area of distribution. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.</description>
    <arm_group_label>Budesonide via Mucosal Atomization Device (MAD)</arm_group_label>
    <other_name>MAD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NeilMed squeeze bottle for Impregnated Nasal Saline Irrigation</intervention_name>
    <description>INSI is delivered using a NeilMed squeeze bottle. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.</description>
    <arm_group_label>Budesonide via nasal saline irrigation (INSI)</arm_group_label>
    <other_name>INSI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged between 19 years and above&#xD;
&#xD;
          -  Patients with chronic or recurrent sinusitis (as defined by the American Academy of&#xD;
             Otolaryngology) with nasal polyposis or allergic fungal rhinosinusitis&#xD;
&#xD;
          -  Patients with an upcoming primary sinus surgery or a revision sinus surgery&#xD;
&#xD;
          -  Patients being prescribed INCS for the first time following Functional Endoscopic&#xD;
             Sinus Surgery (FESS)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals unable to understand the purpose, methods and conduct of this study&#xD;
&#xD;
          -  Patients unwilling to provide informed consent&#xD;
&#xD;
          -  Are immuno-compromised, and have impairment in mucociliary function (e.g., cystic&#xD;
             fibrosis, Kartagener syndrome)&#xD;
&#xD;
          -  Have autoimmune diseases affecting the upper airway (eg Systemic lupus erythematosus,&#xD;
             Sj√∂gren's syndrome, systemic sclerosis etc)&#xD;
&#xD;
          -  Have sinonasal tumors&#xD;
&#xD;
          -  Patients with a history of pituitary disease&#xD;
&#xD;
          -  Patients with a known hypersensitivity to cortisol, corticotropin, or cosyntropin&#xD;
&#xD;
          -  Recent use of systemic corticosteroids such as prednisone (within last 3 months)&#xD;
&#xD;
          -  Patients that are not adherent to budesonide via MAD/INSI treatment&#xD;
&#xD;
          -  Patients who are pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amin Javer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of British Columbia and St. Paul's Sinus Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Atenea Pascual</last_name>
    <phone>(604) 806-9926</phone>
    <email>apascual@providencehealth.bc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Samson</last_name>
    <phone>(604) 806-9926</phone>
    <email>lsamson2@providencehealth.bc.ca</email>
  </overall_contact_backup>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 28, 2020</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2020</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Paul's Hospital, Canada</investigator_affiliation>
    <investigator_full_name>Amin Javer</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Budesonide</keyword>
  <keyword>MAD</keyword>
  <keyword>INSI</keyword>
  <keyword>CRS</keyword>
  <keyword>AFRS</keyword>
  <keyword>Postoperative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We will publish final outcomes as scientific paper.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

